| 12/31/2013 | CV | Outlook 2014: U.S. secondary market poised for continued strength, but investors eye Fed taper
|
| 5/17/2013 | CVLM | Vertex Pharmaceuticals calls $400 million 3.35% convertibles due 2015
|
| 4/22/2013 | CV | Market Commentary: Integra LifeSciences flat to lower; Vertex quiet after surge; Intel, Microsoft in trade
|
| 4/19/2013 | CV | Market Commentary: Vertex higher on drug study data; Cobalt improves dollar-neutral; Intelsat extends gains
|
| 12/4/2012 | CV | Market Commentary: Volcano deal upsized, trades up in gray market; existing Volcano quiet; Seacor deal on tap
|
| 11/13/2012 | CV | Market Commentary: Gilead trades mixed on data; Vertex in line; CEDC sinks in light trade; GT Advanced down
|
| 11/2/2012 | CV | Market Commentary: Dendreon higher after wider loss; Vertex up on hedge after earnings miss; Chesapeake quiet
|
| 8/24/2012 | CV | Market Commentary: Convertibles mostly quiet; Gilead comes in slightly; Vertex static; Endo moves up a little
|
| 8/2/2012 | CV | Market Commentary: Knight swings wildly, extends slide after 'glitch'; Gilead adds on rival's suspended trial
|
| 7/3/2012 | CV | Market Commentary: Convertibles quiet ahead of holiday; Lincare, Theravance extend gains; U.S. Steel better
|
| 5/29/2012 | CV | Market Commentary: Vertex pops on hedge after drug data benefits curbed; coal names eyed; Vishay to price
|
| 5/8/2012 | CV | Market Commentary: Thompson Creek slides; Annaly on tap; Dendreon drops outright, on hedge; Salix seen flat
|
| 5/7/2012 | CV | Market Commentary: Thompson Creek's $200 million unit deal looks cheap; Vertex adds dollar neutral; GM up
|
| 1/9/2012 | CV | Market Commentary: Convertibles revert to 'quiet'; Alcoa firm to better ahead of earnings; Amgen steady
|
| 1/6/2012 | CV | Market Commentary: Convertibles start year strong; Regeneron jumps to 104; Dendreon gains; RF Micro drops
|
| 8/5/2011 | CV | Market Commentary: Convertibles see limited bargain hunting; Vertex up on short covering; high grade firms
|
| 6/10/2011 | CV | Market Commentary: Molycorp jumps on debut, but Integra drops; new Brookside extends losses; Vertex expands
|
| 6/9/2011 | CV | Market Commentary: Brookdale slips on debut; Forestar scraps deal; Molycorp looks cheap after revised talk
|
| 3/29/2011 | CV | Market Commentary: Goodyear slips; InterDigital up in gray; Mentor on tap; A123 short on borrow; Vertex rises
|
| 12/3/2010 | CV | Market Commentary: Clearwire slumps on debut as hedge players steer clear; Vertex below par; Cameron rises
|
| 10/28/2010 | CV | Market Commentary: Energy XXI bid higher in gray market; Flagstar's $270 million preferreds quiet on debut
|
| 9/24/2010 | CV | Market Commentary: Carnival crushed on call; AMD mixed, quiet; convertibles generally better with equity rally
|
| 9/24/2010 | CV | Vertex greenshoe fully exercised, lifts convertibles to $400 million
|
| 9/23/2010 | CV | New Issue: Vertex Pharmaceuticals prices $375 million of five-year convertibles to yield 3.35%, up 35%
|
| 9/23/2010 | CV | Market Commentary: Vertex Pharma adds on active debut; Avis, Hertz slip; Rite Aid down, but CBIZ adds to debut
|
| 9/22/2010 | CV | Market Commentary: CBIZ higher on quiet debut; AMR weaker on disappointing guidance; Vertex to price pre-open
|
| 9/22/2010 | CV | Vertex Pharmaceuticals to price $375 million of five-year convertibles to yield 3%-3.5%, up 35%
|
| 2/19/2010 | CVHY | Vertex Pharmaceuticals files automatic shelf covering stock and debt
|
| 2/16/2010 | CV | Vertex calls $32.1 million 4.75% convertibles for redemption at 102.85
|
| 11/16/2009 | CV | Vertex holders to swap $111.9 million convertibles due 2013 for stock
|
| 11/10/2009 | CV | Vertex to issue stock in exchange for $109 million 4.75% convertibles
|
| 6/11/2009 | CV | Vertex to issue shares in exchange for $143.5 million convertibles
|
| 6/8/2009 | CV | Vertex to issue shares in exchange for $143.5 million of convertibles
|
| 2/14/2008 | CV | Vertex greenshoe exercised, lifts 4.75% convertibles to $287.5 million
|
| 2/13/2008 | CV | Market Commentary: Vertex Pharmaceuticals shines; Nortel up on venture talk; AMD up on EU's Intel raid; SLM upgraded
|
| 2/13/2008 | CV | New Issue: Vertex prices $250 million 4.75% convertible senior notes due 2103, up 35%
|
| 2/12/2008 | CV | Market Commentary: Flotek, GMX Resources price deals cheap; Vertex coming next; Financials mixed on mortgage deal
|
| 2/12/2008 | CV | Vertex prices $250 million convertibles to yield 4.75%, up 35%
|
| 2/11/2008 | CV | Market Commentary: Yahoo! up after rejecting Microsoft; Flotek, Vertex Pharma bringing deals; GM, Schering-Plough earnings ahead
|
| 2/11/2008 | CV | Vertex Pharmaceuticals launches $250 million convertibles due 2013; talked at 4.75%-5.25%, up 27.5%-32.5%
|
| 3/5/2007 | CV | Vertex Pharmaceuticals 5.75% convertible holders convert ahead of redemption
|
| 2/2/2007 | CV | Vertex Pharmaceuticals calls 5.75% convertibles due 2011
|
| 8/3/2006 | BTCV | Vertex Pharmaceuticals to issue 4.1 million shares for $58.3 million 5.75% convertibles
|
| 11/28/2005 | BTCV | Vertex to exchange $95 million convertibles for stock
|
| 9/9/2005 | BTCV | Vertex Pharmaceuticals to exchange $40.45 million convertibles due 2007 for 2.452 million shares
|
| 5/2/2005 | CV | Market Commentary: Corixa converts climb to par on takeover, other biotechs mixed; Calpine higher; Primus plunges
|
| 4/1/2005 | CV | Vertex Pharmaceuticals files $200 million shelf
|
| 9/13/2004 | CV | Vertex exchanges $79.3 million convertibles for new notes
|
| 2/10/2004 | CV | Vertex exchanges $153.5 million 5% convertibles
|
| 8/8/2002 | CV | Salomon halts shift to equity-sensitive issues in recommended convertibles portfolio
|
| 6/12/2002 | CV | Deutsche on biopharma: buy Inhale, Cell Therapeutics; hold Abgenix, Alexion; sell Vertex, ISIS
|
| 5/7/2002 | CV | Salomon adds three, removes three from recommended portfolio
|
| 4/10/2002 | CV | JPMorgan recommends 9 biotech convertibles for yield, capital appreciation, relative value
|
| 11/14/2001 | CV | Salomon says Vertex Pharmaceuticals risk worth the yield for tolerant investors
|
